PMC6081528_01
Time course of omalizumab's effect on AE-QoL score in the two patients (clear and black squares) with InH-AAE. Both patients showed a rapid response to omalizumab and during the 6-month treatment the patients were free of AE attacks. Two months after suspension one patient (black squares) had symptom recurrences and therefore was retreated with omalizumab.
CRII2018-8067610.001.jpg
PMC6081528_01_CRII2018-8067610.001.jpg
fig1
He remained AE attack free during the entire treatment period and for 6 months after treatment suspension (Figure 1). AE attacks recurred and treatment was resumed. At the 4 months follow-up visit he was symptom free (Figure 1).